Amgen, AstraZeneca, Covance, PAREXEL, PPD, and PRA Health Sciences Renew Partnerships with SCRS
Contact:
Mary D’Rozario
Director of Communications
Society for Clinical Research Sites
919.890.5513
mary.drozario@myscrs.org
FOR IMMEDIATE RELEASE
Amgen, AstraZeneca, Covance, PAREXEL, PPD, and PRA Health Sciences Renew Partnerships with SCRS
Ellicott City, MD, August 15, 2017 — The Society for Clinical Research Sites (SCRS) today announced the renewal of Global Impact Partnerships (GIP) with Amgen, AstraZeneca, Covance, PAREXEL, PPD, and PRA Health Sciences. This two-year GIP commitment includes serving on the SCRS Global Impact Board at an executive level, and working with the SCRS Leadership Council on strategic initiatives to promote high-level communication and meaningful collaboration between industry stakeholders and global clinical research sites.
“As GIPs, these companies demonstrate their commitment to strengthening their relationships with sites through their collaboration with SCRS.” said Christine Pierre, president of SCRS. “Meaningful collaboration between sites and other stakeholders is critical to bring new products to market, and we are pleased to see these leading organizations taking action to ensure this reality.”
###
About SCRS
About SCRS
SCRS is a global trade organization founded in 2012 which represents almost 9,000 research sites in over 45 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Our Voice. Our Community. Your Success. Join the community and collaborate with the global experts in site sustainability. Visit MySCRS.org.
